BNP Paribas Asset Management’s Idexx Laboratories IDXX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $69.8M | Buy |
132,512
+19,024
| +17% | +$10.7M | 0.07% | 263 |
|
|
2026
Q1 | $63.8M | Buy |
113,488
+3,627
| +3% | +$2.33M | 0.07% | 260 |
|
|
2025
Q4 | $74.3M | Buy |
109,861
+8,954
| +9% | +$6.1M | 0.09% | 223 |
|
|
2025
Q3 | $64.4M | Buy |
100,907
+1,080
| +1% | +$656K | 0.17% | 127 |
|
|
2025
Q2 | $53.5M | Sell |
99,827
-228
| -0.2% | -$109K | 0.13% | 158 |
|
|
2025
Q1 | $42M | Buy |
100,055
+23,177
| +30% | +$10.1M | 0.11% | 194 |
|
|
2024
Q4 | $31.8M | Buy |
76,878
+3,401
| +5% | +$1.49M | 0.08% | 248 |
|
|
2024
Q3 | $37.1M | Buy |
73,477
+3,382
| +5% | +$1.64M | 0.09% | 220 |
|
|
2024
Q2 | $34.1M | Sell |
70,095
-70,670
| -50% | -$35.5M | 0.09% | 231 |
|
|
2024
Q1 | $76M | Sell |
140,765
-24,377
| -15% | -$13.3M | 0.2% | 111 |
|
|
2023
Q4 | $91.7M | Buy |
165,142
+1,553
| +0.9% | +$729K | 0.26% | 102 |
|
|
2023
Q3 | $71.5M | Buy |
163,589
+24,901
| +18% | +$12.4M | 0.22% | 115 |
|
|
2023
Q2 | $69.7M | Buy |
138,688
+73,018
| +111% | +$35M | 0.22% | 112 |
|
|
2023
Q1 | $32.8M | Sell |
65,670
-10,572
| -14% | -$5.06M | 0.11% | 198 |
|
|
2022
Q4 | $31.1M | Sell |
76,242
-43,094
| -36% | -$16.7M | 0.11% | 212 |
|
|
2022
Q3 | $38.9M | Sell |
119,336
-1,941
| -2% | -$713K | 0.15% | 150 |
|
|
2022
Q2 | $42.5M | Buy |
121,277
+14,004
| +13% | +$5.71M | 0.16% | 151 |
|
|
2022
Q1 | $58.7M | Buy |
107,273
+40,135
| +60% | +$21.1M | 0.2% | 115 |
|
|
2021
Q4 | $44.2M | Sell |
67,138
-1,819
| -3% | -$1.14M | 0.15% | 174 |
|
|
2021
Q3 | $42.9M | Buy |
68,957
+14,462
| +27% | +$9.72M | 0.16% | 158 |
|
|
2021
Q2 | $34.4M | Buy |
54,495
+7,317
| +16% | +$4.04M | 0.12% | 209 |
|
|
2021
Q1 | $23.1M | Buy |
47,178
+1
| +0% | +$501 | 0.1% | 249 |
|
|
2020
Q4 | $23.6M | Buy |
47,177
+6,835
| +17% | +$3.06M | 0.11% | 225 |
|
|
2020
Q3 | $15.9M | Buy |
40,342
+7,093
| +21% | +$2.62M | 0.09% | 251 |
|
|
2020
Q2 | $11M | Buy |
33,249
+2,407
| +8% | +$697K | 0.07% | 287 |
|
|
2020
Q1 | $7.47M | Buy |
30,842
+2,158
| +8% | +$563K | 0.06% | 305 |
|
|
2019
Q4 | $7.49M | Buy |
28,684
+7,593
| +36% | +$2M | 0.05% | 380 |
|
|
2019
Q3 | $5.74M | Buy |
21,091
+14,347
| +213% | +$3.99M | 0.04% | 420 |
|
|
2019
Q2 | $1.86M | Buy |
6,744
+748
| +12% | +$184K | 0.02% | 573 |
|
|
2019
Q1 | $1.34M | Sell |
5,996
-823
| -12% | -$170K | 0.01% | 657 |
|
|
2018
Q4 | $1.27M | Buy |
6,819
+1,877
| +38% | +$385K | 0.01% | 667 |
|
|
2018
Q3 | $1.23M | Buy |
4,942
+185
| +4% | +$44.9K | 0.01% | 672 |
|
|
2018
Q2 | $1.04M | Buy |
4,757
+394
| +9% | +$81.2K | 0.01% | 732 |
|
|
2018
Q1 | $835K | Sell |
4,363
-5,986
| -58% | -$1.1M | 0.01% | 758 |
|
|
2017
Q4 | $1.62M | Sell |
10,349
-32,789
| -76% | -$5.16M | 0.01% | 673 |
|
|
2017
Q3 | $6.71M | Sell |
43,138
-6,953
| -14% | -$1.1M | 0.06% | 426 |
|
|
2017
Q2 | $8.09M | Buy |
50,091
+3,022
| +6% | +$491K | 0.07% | 371 |
|
|
2017
Q1 | $7.28M | Buy |
47,069
+42,815
| +1,006% | +$5.9M | 0.07% | 396 |
|
|
2016
Q4 | $499K | Sell |
4,254
-21,102
| -83% | -$2.41M | ﹤0.01% | 858 |
|
|
2016
Q3 | $2.86M | Buy |
25,356
+21,886
| +631% | +$2.31M | 0.02% | 636 |
|
|
2016
Q2 | $322K | Buy |
+3,470
| New | +$298K | ﹤0.01% | 1023 |
|
Other funds holding IDXX
BNP Paribas Asset Management's IDXX Position: Q2 2026 in Review
BNP Paribas Asset Management increased its Idexx Laboratories (IDXX) stake by 17% in Q2 2026, buying an estimated $10.7M and bringing the position to 132,512 shares worth $69.8M. The position accounts for 0.07% of the portfolio, ranked #263.
BNP Paribas Asset Management first reported a position in IDXX in Q2 2016 and has held it in 41 quarters since. The position peaked at $91.7M in Q4 2023. 1,296 funds tracked by Wall St. Rank hold IDXX as of Q2 2026.
- BNP Paribas Asset Management held 132,512 shares of Idexx Laboratories worth $69.8M as of Q2 2026.
- BNP Paribas Asset Management bought 19,024 Idexx Laboratories shares in Q2 2026, an estimated $10.7M.
- Idexx Laboratories made up 0.07% of BNP Paribas Asset Management's portfolio in Q2 2026, its #263 holding.
- BNP Paribas Asset Management first reported a position in Idexx Laboratories in Q2 2016 and has held it in 41 quarters since.
- BNP Paribas Asset Management's Idexx Laboratories position peaked at $91.7M in Q4 2023.
- 1,296 funds tracked by Wall St. Rank held Idexx Laboratories as of Q2 2026.
Based on BNP Paribas Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.